PMGC Holdings (ELAB) Total Liabilities (2022 - 2026)
PMGC Holdings' (ELAB) quarterly Total Liabilities came in at $19.8 million in Q2 2026, up 5976.47% year-over-year from $326301.0 in Q2 2025, and up 47.67% quarter-over-quarter from $13.4 million in Q1 2026.
Analysis
PMGC Holdings (ELAB) Total Liabilities (2022 - 2026) Analysis & Trends
PMGC Holdings has disclosed Total Liabilities across 5 years of filings, most recently posting $19.8 million for Q2 2026.
- In Q2 2026, Total Liabilities rose 5976.47% year-over-year to $19.8 million; the TTM figure through Jun 2026 stood at $19.8 million (up 5976.47% YoY), while the FY2025 annual figure was $5.0 million, up 115.59% from the prior year.
- Total Liabilities came in at $19.8 million for Q2 2026 at PMGC Holdings, up from $13.4 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $1.7 billion in Q3 2023 to a low of -$1.6 billion in Q3 2022.
- Average Total Liabilities over 5 years is $11.5 million, with a median of $2.0 million recorded in 2024.
- Year-over-year, Total Liabilities slumped 99.85% in 2024 and jumped 5976.47% in 2026.
- Over 5 years, Total Liabilities stood at $760873.0 in 2022, then soared by 79.12% to $1.4 million in 2023, then surged by 71.23% to $2.3 million in 2024, then jumped by 115.59% to $5.0 million in 2025, then jumped by 294.1% to $19.8 million in 2026.
- Per Business Quant data, the three most recent Total Liabilities figures were $19.8 million in Q2 2026, $13.4 million in Q1 2026, and $5.0 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.40 Bn | 192.42 Bn | 7.24 Bn | 83.95 Bn |
| 2 | Gilead Sciences | 180.38 Bn | 177.20 Bn | 6.22 Bn | 37.53 Bn |
| 3 | Vertex Pharmaceuticals | 131.28 Bn | 123.43 Bn | 2.84 Bn | 7.18 Bn |
| 4 | Regeneron Pharmaceuticals | 81.73 Bn | 73.73 Bn | 3.93 Bn | 10.02 Bn |
| 5 | Argenx Se | 60.28 Bn | 55.09 Bn | 1.37 Bn | 1.62 Bn |
| 6 | Moderna | 54.02 Bn | 48.88 Bn | 52.00 Mn | 4.20 Bn |
| 7 | Alnylam Pharmaceuticals | 33.28 Bn | 29.97 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Biogen | 31.81 Bn | 30.52 Bn | 1.96 Bn | 13.24 Bn |
| 9 | Roivant Sciences | 29.02 Bn | 29.02 Bn | 1.16 Mn | 384.62 Mn |
| 10 | PMGC Holdings | 2.29 Mn | -16.50 Mn | 385,691.00 | 19.83 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 19.83 Mn |
| Mar 31, 2026 | 13.43 Mn |
| Dec 31, 2025 | 5.03 Mn |
| Sep 30, 2025 | 6.45 Mn |
| Jun 30, 2025 | 326,301.00 |
| Mar 31, 2025 | 760,268.00 |
| Dec 31, 2024 | 2.33 Mn |
| Sep 30, 2024 | 2.65 Mn |
| Jun 30, 2024 | 2.44 Mn |
| Mar 31, 2024 | 1.74 Mn |
| Dec 31, 2023 | 1.36 Mn |
| Sep 30, 2023 | 1.75 Bn |
| Jun 30, 2023 | -67,288.00 |
| Mar 31, 2023 | -913,388.00 |
| Dec 31, 2022 | 760,873.00 |
| Sep 30, 2022 | -1.62 Bn |